{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:06:54Z","timestamp":1771002414711,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2026.104699","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:28:50Z","timestamp":1768202930000},"page":"104699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-2537","authenticated-orcid":false,"given":"Justyna","family":"\u017bubrowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Pieni\u0105\u017cek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Ru\u0161inov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e1ta","family":"Soumarov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Konieczna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"M\u0142odzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Winsko-Szcz\u0119snowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Lisik-Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9087-6126","authenticated-orcid":false,"given":"Anika","family":"P\u0119kala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Krej\u010d\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"\u0160ustr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iveta","family":"Kol\u00e1\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Szymanik-Resko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Ciszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milo\u0161","family":"Hol\u00e1nek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogumi\u0142a","family":"Czartoryska-Ar\u0142ukowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"\u0141acko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Smok-Kalwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Pacholczak-Madej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"\u0141ugowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Biel\u010dikov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslava","family":"Malej\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.breast.2026.104699_bib1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.breast.2026.104699_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104699_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"10265","key":"10.1016\/j.breast.2026.104699_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.breast.2026.104699_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.breast.2026.104699_bib6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104699_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104699_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2026.104699_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104699_bib10","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2026.104699_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"The Breast"},{"issue":"12","key":"10.1016\/j.breast.2026.104699_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104699_bib13","unstructured":"Guidelines detail. NCCN. Accessed August 20, 2025. .https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"issue":"3","key":"10.1016\/j.breast.2026.104699_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf034","article-title":"Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States","volume":"30","author":"Punie","year":"2025","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.breast.2026.104699_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100225","article-title":"Care of the adult cancer patient at the end of life: ESMO clinical practice guidelines","volume":"6","author":"Crawford","year":"2021","journal-title":"ESMO Open"},{"issue":"19","key":"10.1016\/j.breast.2026.104699_bib16","first-page":"2336","article-title":"Palliative care for patients with cancer: ASCO guideline update","volume":"42","author":"Sanders","year":"2024","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.breast.2026.104699_bib17","first-page":"169","article-title":"Termination of palliative chemotherapy near the end of life: a retrospective study of gastrointestinal cancer patients","volume":"4","author":"Matsumoto","year":"2023","journal-title":"Palliat Med Rep"},{"issue":"11","key":"10.1016\/j.breast.2026.104699_bib18","first-page":"3277","article-title":"Chemotherapy in the last 30 days of life of advanced cancer patients","volume":"23","author":"Pacetti","year":"2015","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.breast.2026.104699_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12094-012-0847-6","article-title":"Chemotherapy at the end of life: up until when?","volume":"14","author":"Sanz Ortiz","year":"2012","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104699_bib20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-020-05663-w","article-title":"Chemotherapy use near the end-of-life in patients with metastatic breast cancer","volume":"181","author":"Edman Kessler","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2026.104699_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0825859719851484","article-title":"Anticancer therapy at the end of life: lessons from a community cancer institute","volume":"36","author":"Sivendran","year":"2021","journal-title":"J Palliat Care"},{"issue":"1","key":"10.1016\/j.breast.2026.104699_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0971-5851.151792","article-title":"Time from last chemotherapy to death and its correlation with the end of life care in a referral hospital","volume":"36","author":"Karim","year":"2015","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104699_bib23","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1177\/1049909120985234","article-title":"A multicenter retrospective review of systemic anti-cancer treatment and palliative care provided to solid tumor oncology patients in the 12 weeks preceding death in Ireland","volume":"38","author":"Mallett","year":"2021","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.breast.2026.104699_bib24","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.2147\/JMDH.S422391","article-title":"Aggressiveness of cancer care at end of life in patients with metastatic breast cancer in Jordan","volume":"16","author":"Abunasser","year":"2023","journal-title":"JMDH"},{"issue":"6","key":"10.1016\/j.breast.2026.104699_bib25","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.breast.2026.104699_bib26","doi-asserted-by":"crossref","first-page":"2809816","DOI":"10.21037\/apm-20-273","article-title":"Use of palliative chemotherapy near the end of life: a retrospective cohort study","volume":"9","author":"Zhang","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"21","key":"10.1016\/j.breast.2026.104699_bib27","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1002\/cncr.35488","article-title":"Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life","volume":"130","author":"George","year":"2024","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104699_bib28","first-page":"92","article-title":"Effect of a patient-centered communication intervention on oncologist-patient communication, quality of life, and health care utilization in advanced cancer: the VOICE randomized clinical trial","volume":"3","author":"Epstein","year":"2017","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.breast.2026.104699_bib29","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.3390\/jcm13226739","article-title":"Time from final oncologist visit to death and palliative systemic treatment use near the end of life in heavily pretreated patients with luminal breast cancer","volume":"13","author":"P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.breast.2026.104699_bib30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s11864-023-01115-x","article-title":"Systemic anticancer treatment near the end of life: a narrative literature review","volume":"24","author":"Geyer","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104699_bib31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s10147-018-1363-7","article-title":"Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer","volume":"24","author":"Hiramoto","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104699_bib32","series-title":"NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life | request PDF","year":"2025"},{"issue":"10","key":"10.1016\/j.breast.2026.104699_bib33","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers16101791","article-title":"Overall survival and prognostic factors in metastatic triple-negative breast cancer: a national cancer database analysis","volume":"16","author":"Kesireddy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.breast.2026.104699_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/jpm.2018.0092","article-title":"Communication differences between oncologists and palliative care clinicians: a qualitative analysis of early, integrated palliative care in patients with advanced cancer","volume":"22","author":"Thomas","year":"2019","journal-title":"J Palliat Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104699_bib35","first-page":"880","article-title":"American society of clinical oncology provisional clinical opinion: the integration of palliative care into standard oncology care","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Orthod"},{"issue":"9_Supplement","key":"10.1016\/j.breast.2026.104699_bib36","article-title":"Abstract PO4-06-13: palliative care utilization in triple negative metastatic breast cancer patients and impact on survival: a nationwide analysis","volume":"84","author":"Kashanian","year":"2024","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.breast.2026.104699_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101709","article-title":"Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study","volume":"45","author":"Lapeyre-Prost","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.breast.2026.104699_bib38","series-title":"EAPC atlas of palliative care in the European Region 2025","author":"Garralda","year":"2025"},{"key":"10.1016\/j.breast.2026.104699_bib39","unstructured":"Work Package 6 \u2013 Palliative care. JANE. Accessed September 17, 2025.https:\/\/jane-project.eu\/project\/the-project\/work-package-6-palliative-care\/."},{"issue":"1","key":"10.1016\/j.breast.2026.104699_bib40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s41687-025-00907-z","article-title":"Development of a unified system for assessing health related quality of life across the cancer care continuum: the EUonQoL Delphi study to identify priorities for quality of life domains","volume":"9","author":"Sweegers","year":"2025","journal-title":"J Patient-Rep Outcomes"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:10:48Z","timestamp":1770999048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"alternative-id":["S0960977626000093"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104699","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104699"}}